Salarius Pharmaceuticals Inc

NASDAQ:SLRX   10:03:46 AM EDT
0.87
0.00 (+0.46%)
Products, Regulatory

Salarius Pharmaceuticals Announces New Clinical Trial To Study Seclidemstat In Hematologic Cancers

Published: 06/15/2021 11:39 GMT
Salarius Pharmaceuticals Inc (SLRX) - Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers.
Salarius Pharmaceuticals Inc - Trial Will Be an Open Label, Dose-finding, Dose-expansion Study.
Salarius Pharmaceuticals Inc - Dose-escalation Stage of Phase 1/2 Trial Will Enroll Patients Aged 18 and Older With Mds Or Cmml.
Salarius - Funding for Trial Will Be Provided by Md Anderson and Salarius, With Co Also Providing Seclidemstat to Investigators for Clinical Trial.